cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-08-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
==== Off-chip incubation ==== Droplets containing cells can be stored off-chip in PTFE tubing for up to several days while maintaining cell viability and allowing for reinjection onto another device for analysis. Evaporation of aqueous and oil-based fluids has been reported with droplet storage in PTFE tubing, so for storage longer than several days, glass capillaries are also used. Finally, following formation in a microfluidic device, droplets may also be guided through a system of capillaries and tubing leading to a syringe. Droplets can be incubated in the syringe and then directly injected onto another chip for further manipulation or detection and analysis.
The 1996 UEFA Champions League final was a football match played on 22 May 1996 between title holders Ajax of the Netherlands and Juventus of Italy. The match ended in a 1–1 draw after extra time, forcing a penalty shoot-out, which Juventus won 4–2. It was the club's second and most recent triumph in the competition. As of 2026, this is the last time a Dutch team appeared in a Champions League final.
=== Stalemate develops between Smith and Wilson === Smith wrote to Wilson the day after the referendum, asking him to send Bottomley to Salisbury for talks. Wilson replied that Smith should instead come to London. The British and Rhodesians exchanged often confrontational letters for the next few months. Alluding to the British financial aid pledged to Salisbury as part of the Federal dissolution arrangements, Wilson's High Commissioner in Salisbury, J B Johnston, wrote to the Rhodesian Cabinet Secretary Gerald B. Clarke on 23 December that "talk of a unilateral declaration of independence is bound to throw a shadow of uncertainty on the future financial relations between the two governments". Smith was furious, seeing this as blackmail, and on 13 January 1965 wrote to Wilson: "I am so incensed at the line of your High Commissioner's letter that I am replying directly to you ... It would appear that any undertakings given by the British government are worthless ... such immoral behaviour on the part of the British government makes it impossible for me to continue negotiations with you with any confidence that our standards of fair play, honesty and decency will prevail."
Sources: en.wikipedia.org
== History == 1979-1988: Research scientist and Senior research scientist of First Institute of Biochemistry, Semmelweis University Medical School and Hungarian Academy of Sciences 1988-1994: Head of Peptide Research Laboratory, Associate Professor of Biochemistry, Joint Research Organization of the Hungarian Academy of Sciences and Semmelweis University Medical School, The First Institute of Biochemistry 1994-2008: Head of Peptide Biochemistry Research Group and Rational Drug Design Laboratory, Professor of Biochemistry, Department of Medicinal Chemistry, Semmelweis Medical University 1992-1999: Scientific advisor of Sugen 1999-2005: Scientific advisor of Axxima Pharmaceuticals 1999–present: CEO and CSO of Vichem Chemie Research Ltd. 2001-2012: Chairman of Rational Drug Design Laboratories Co-operation Research Center, Semmelweis University 2002-2008: Curator of Office for Subsidised Research Units of Hungarian Academy of Sciences 2008-2012: Head of Signal Transduction Therapy Laboratory at Semmelweis University 2012–present: Head of Pathobiochemistry Research Group of Hungarian Academy of Sciences at Semmelweis University, Department of Medical Chemistry
==== Papillary region ==== The papillary region is composed of loose areolar connective tissue. It is named for its finger-like projections called papillae, which extend toward the epidermis. The papillae provide the dermis with a "bumpy" surface that interdigitates with the epidermis, strengthening the connection between the two layers of skin. In the palms, fingers, soles, and toes, the influence of the papillae projecting into the epidermis forms contours in the skin's surface. These epidermal ridges occur in patterns (see: fingerprint) that are genetically and epigenetically determined and are therefore unique to the individual, making it possible to use fingerprints or footprints as a means of identification.
== Contraindications == Methamphetamine is contraindicated in individuals with a history of substance use disorder, heart disease, or severe agitation or anxiety, or in individuals currently experiencing arteriosclerosis, glaucoma, hyperthyroidism, or severe hypertension. The FDA states that individuals who have experienced hypersensitivity reactions to other stimulants in the past or are currently taking monoamine oxidase inhibitors should not take methamphetamine. The FDA also advises individuals with bipolar disorder, depression, elevated blood pressure, liver or kidney problems, mania, psychosis, Raynaud's phenomenon, seizures, thyroid problems, tics, or Tourette syndrome to monitor their symptoms while taking methamphetamine. Owing to the potential for stunted growth, the FDA advises monitoring the height and weight of growing children and adolescents during treatment.
Sources: en.wikipedia.org
In living cells, DNP acts as a protonophore, an agent that can shuttle protons (hydrogen cations) across biological membranes. It dissipates the proton gradient across the mitochondrial membrane, collapsing the proton motive force that the cell uses to produce most of its ATP chemical energy. Instead of producing ATP, the energy of the proton gradient is lost as heat. The inefficiency is proportional to the dose of DNP that is taken. As the dose increases and energy production is made more inefficient, metabolic rate increases (and more fat is burned) in order to compensate for the inefficiency and to meet energy demands. DNP is probably the best known agent for uncoupling oxidative phosphorylation. The phosphorylation of adenosine diphosphate (ADP) by ATP synthase gets disconnected or uncoupled from oxidation. DNP raises the basal metabolic rate (BMR) and lowers T4 (thyroid hormone) levels by increasing T4 metabolism and reducing thyroid hormone secretion. Because it binds to thyroxine-binding globulin, overall thyroid function may not be affected. DNP cannot substitute for thyroid hormone in myxedema.
Daphne Walker, singer (born 1930). 19 July – Lee Mummery, cricketer (Central Districts) (born 1935). 20 July – Jim Tomlin, artist, musician (Chants R&B), and art educator (Otago Polytechnic) (born 1940). 23 July – Kathryn Smits, Germanist (University of Auckland) (born 1935). 25 July – Ian Leggat, school teacher and university administrator, principal of Hagley High School (1971–1976) and Christchurch Boys' High School (1976–1988), University of Canterbury chancellor (1992–1998) (born 1929). 26 July Ian Carter, sociologist (University of Auckland) (born 1943). Keith Sorrenson, historian (University of Auckland), president of the Citizens' Association for Racial Equality (1971–1973), member of the Waitangi Tribunal (1986–2011) (born 1932). John Werry, child and adolescent psychiatrist (University of Auckland) (born 1931). 29 July – Sir Michael Hill, jeweller, businessman (Michael Hill Jeweller), and philanthropist (born 1938).
Upregulation An increase in the number or sensitivity of receptors on a neuron, often in response to reduced stimulation or drug exposure. A mechanism of plasticity. Utricle A structure within the vestibular system that detects linear acceleration and head position relative to gravity. Works in tandem with the saccule. Uveitis Inflammation of the uveal tract (including the iris, ciliary body, and choroid), which can cause visual disturbances and is sometimes associated with autoimmune neurological disorders.
Ingram Cecil Connor III (November 5, 1946 – September 19, 1973), known professionally as Gram Parsons, was an American musician. He recorded with the International Submarine Band, the Byrds, and the Flying Burrito Brothers, popularizing what he called "Cosmic American Music", a hybrid of country, rhythm and blues, soul, folk, and rock. He has been credited with helping to found the country rock and alt-country genres and received a ranking of No. 87 on Rolling Stone magazine's list of the 100 Greatest Artists of All Time. Parsons was posthumously inducted into the Rock and Roll Hall of Fame in 2026 in the musical influence category.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.